Antisense Therapeutics Limited (ANP)

Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

Sign Up Today Ľ it's FREE! Already a member? Login now!

General Information
Company Name: Antisense Therapeutics Limited
Stock Code: ANP
GICS Sub-Industry: Pharmaceuticals
Market Cap ($M): 19
Equiv. Shares (M): 144

Current Price Data+
Current Price Open High Low Last Close Volume Price Movement
 $ 0.130 $ 0.135 $ 0.135 $ 0.130 $ 0.135 178,668 $ -0.005  -3.704 %

Company Overview

Business Description:
Antisense Therapeutics Limited (ANP) is a biopharmaceutical drug discovery and development company. ANP develops and commercialises second generation antisense pharmaceuticals for large unmet markets. ANP has four products including ATL1102 injection for Multiple Sclerosis, ATL1103 injection for growth & sight disorders, ATL1101 injection for prostate cancer, and ATL1102 inhaled for asthma.

Financial Summary
Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2014  A -3.0 -2.1 -- 0.0 0.0 0.0 --
2013  A -2.5 -1.7 -- 0.0 0.0 0.0 --
2012  A -1.8 -1.8 -- 0.0 0.0 0.0 --
Source: Morningstar analyst estimates.

Peer Comparison
EPS Growth (%) P/E (%) Dividend Yield (%)
Company Mkt Cap 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F
Acrux Limited (ACR) $208 M 3.0384 0.4929 0.1627 7.4405 4.9841 4.2867 16.00 7.60 8.30
Antisense Therapeutics (ANP) $19 M -- -- -- -- -- -- 0.00 -- --
Mayne Pharma Group (MYX) $441 M 1.0457 -0.0064 0.2830 23.9617 24.1158 18.7970 0.00 0.00 0.00

Market Comparison
Earnings P/E Ratio P/B Ratio P/E Growth P/S Ratio
ANP -- -- 8.97 -- --
Market 1.12 13.9 1.00 1.04 3.54
Sector 0.68 22.0 3.19 1.36 8.42

Name Position Start Date
Mr Robert William Moses Chairman 23 October 2001
Mr Mark P Diamond Managing Director 31 October 2001
Dr Christopher (Chris) Belyea Non-Executive Director 13 November 2000
Professor Graham Mitchell Non-Executive Director 24 October 2001

Name Position
Phillip Hains Chief Financial Officer, Company Secretary
George Tachas Director, Drug Discovery & Patents

Substantial Shareholders
Holding Name
143,149,187 (9.93%) Polychip Pharmaceuticals Pty Ltd
87,920,107 (6.10%) Jason + Catherine Constable

Calendar of Events
Date Event
24 August 2015 Report (Prelim)
23 February 2015 Report (Interim)
30 September 2014 Report (Annual)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at


Trade Shares Online from $19.95^
Free Guides

The SMH Guide to Investing in Unlisted Property Trusts

A property trust allows you to buy 'units' in an investment operated by a professional investment manager. This Guide will help you understand the risks and decide whether to invest your money.

More details...


Billionaires bankroll Ten's new direction Media Network sees digital future

The Age 19/12/2013 | Ten Network's programming ambitions will be funded by a $200 million loan guaranteed by three of its billionaire owners, as the free-to-air broadcaster declared digital was the future and pointed to early signs that its switch to an older market demographic was working.

Elders alleges $24m fraud in live cattle division

The Age 19/12/2013 | Troubled rural services group Elders is threatening to call in the police over an alleged $24 million fraud by a "handful of individuals" in its live cattle exports division.

Bega Cheese holds back in three-way bidding war for WCB

The Age 19/12/2013 | Bega Cheese began the battle for Warrnambool Cheese & Butter but three months on it appears to be the first casualty of the bidding war.

Aussie hampers transition

The Age 19/12/2013 | A persistently high Australian dollar is thwarting the Reserve Bank's efforts to ease the transition of the economy away from mining.

RBA keeps its focus on lower dollar

The Age 19/12/2013 | The Reserve Bank is keeping the door open to further interest rate cuts, but believes the "significant amount" of monetary policy easing over the past two years is already stimulating growth.

Pact's struggles weigh down Orora

The Age 19/12/2013 | The underwhelming sharemarket debut of packaging company Pact Group Holdings has weighed on the demerger of Amcor and its $2 billion Australasian packaging and distribution business Orora.


Sponsored Links